Graphene Investments SAS Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Graphene Investments SAS reduced its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 24,200 shares of the specialty pharmaceutical company’s stock after selling 2,800 shares during the quarter. Jazz Pharmaceuticals accounts for about 2.1% of Graphene Investments SAS’s investment portfolio, making the stock its 20th largest holding. Graphene Investments SAS’s holdings in Jazz Pharmaceuticals were worth $2,980,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 121 shares in the last quarter. UMB Bank n.a. grew its position in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. Ellsworth Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after buying an additional 149 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in Jazz Pharmaceuticals by 2.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock valued at $868,000 after buying an additional 155 shares during the period. Finally, Cooper Financial Group grew its position in Jazz Pharmaceuticals by 3.7% during the fourth quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 156 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 5,053 shares of company stock worth $617,442 over the last quarter. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $120.07 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market cap of $7.26 billion, a P/E ratio of 16.91, a P/E/G ratio of 0.90 and a beta of 0.56. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17. The firm has a 50-day moving average of $122.60 and a 200-day moving average of $116.32.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.